Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: Pharmacogenet Genomics. 2014 Feb;24(2):118–128. doi: 10.1097/FPC.0000000000000026

FIGURE 5.

FIGURE 5

Novel variants were associated with slow nicotine metabolizers in vivo as indicated by lower group means compared to CYP2A6 *1/*1 genotype group. Novel variants are shown individually along the X axis as well as together as a group (combined). Variant R265Q had three individuals identified via sequencing and variants V68M and L462P had one individual identified via sequencing (the remaining individuals within these variant groups were identified via genotyping). Association with lower activity of the novel variant groups was tested using a one-way analysis of variance with Bonferroni tests used for post-hoc analysis **P<0.01. A comparison between CYP2A6*1/*1 and the combined group was tested using an unpaired t-test ***P<0.001. Inset indicates the lack of association between 51G>A (rs1137155) among the CYP2A6*1/*1 individuals.